Task_2_C204___ES.docx C204 Management Communication C204 Task 2 Western Governors University Executive Summary: Marketing Strategy: Nasaquil This report summarizes the marketing strategy meeting held on February 2
...
Task_2_C204___ES.docx C204 Management Communication C204 Task 2 Western Governors University Executive Summary: Marketing Strategy: Nasaquil This report summarizes the marketing strategy meeting held on February 28th, 2020 for Nasaquil. This report will include the effects of this newly released medication, highlighting the clinical trial findings, and prescription information for patients. Within this meeting, there were three key points that our client, Nasaquil wanted covered: Reduction in severity and duration of symptoms Supported through clinical trials Reduction in wait time – due to no prescription required When discussing the reduction in severity and duration, the presenter highlighted the average duration of influenza was generally 7-10 days, however with treatment with Nasaquil it reduced symptoms to 3-5 days. Additionally, overall severity of symptoms was reduced (nausea, vomiting, diarrhea, etc. were mentioned). When discussing the clinical trial data, Nasaquil wanted to ensure that proper information was being shared – small sample population size and no long-term efficacy rates have been determined yet due to Nasaquil being newly released. Lastly, the reduction of wait time as it pertains to obtaining a prescription. Nasaquil wanted to highlight this medication is available Over-The-Counter and does not require scheduling an appointment with the patients Primary care physician – which could delay treatment by a few days. Also, was mentioned that Urge. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . .. .. . . . . . . . . . . . . . . . . . .. . . . .
[Show More]